|
Title
|
|
|
|
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy : VISION Cohort B
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| High-level MET amplification (METamp) is a primary driver in-1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level METamp who were enrolled by liquid biopsy. While the study was halted before the enrollment of the planned 60 patients, the results of 24 enrolled patients are presented here. The objective response rate (ORR) is 41.7% (95% confidence interval [CI], 22.1-63.4), and the median dura-tion of response is 14.3 months (95% CI, 2.8-not estimable). In exploratory biomarker analyses, focal METamp, RB1 wild-type, MYC diploidy, low circulating tumor DNA (ctDNA) burden at baseline, and early mo-lecular response are associated with better outcomes. Adverse events include edema (composite term; any grade: 58.3%; grade 3: 12.5%) and constipation (any grade: 41.7%; grade 3: 4.2%). Tepotinib provides anti-tumor activity in high-level METamp NSCLC (ClinicalTrials.gov: NCT02864992). |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Cell reports medicine
| |
|
Publication
|
|
|
|
2023
| |
|
DOI
|
|
|
|
10.1016/J.XCRM.2023.101280
| |
|
Volume/pages
|
|
|
|
4
:11
(2023)
, p. 1-15
| |
|
Article Reference
|
|
|
|
101280
| |
|
ISI
|
|
|
|
001124453600001
| |
|
Pubmed ID
|
|
|
|
37944528
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|